{"title":"Stress kinases negatively regulate the multipotency of mesenchymal stem/stromal cells <i>in vitro</i>: implications in regenerative medicine.","authors":"Prajakta Teli, Anuradha Vaidya, Vaijayanti Kale","doi":"10.1080/17460751.2026.2665223","DOIUrl":null,"url":null,"abstract":"<p><p>The therapeutic efficacy of Mesenchymal stromal cells (MSCs) has been attributed to two mechanisms: one, the transdifferentiation of MSCs into tissue-specific cells and their integration into the affected tissue, and two, the reparative effects of their secretome. While the latter mechanism is now widely accepted, the ability of MSCs to transdifferentiate into non-mesodermal lineages remains highly debated. Nonetheless, several recent studies have shown that MSCs can differentiate into non-mesodermal lineages under specialized conditions. These studies are reviewed here. Notably, cultured MSCs exhibit activation of stress-kinases, and inhibition of these kinases has been shown to enhance the regenerative potential of MSCs; however, the underlying mechanisms involved in this improved potency remain poorly understood. This review also covers existing literature on the effects of stress kinase inhibition on MSC differentiation and functional potency, with an emphasis on therapeutic implications. Here, we propose a novel hypothesis that under conventional culture conditions, stress kinases negatively regulate the differentiation potency of MSCs and limit their multi-lineage potential. Inhibition of these kinases may not drive full lineage commitment that could qualify as transdifferentiation, but instead induce a quasi-differentiated or \"primed\" MSC state. Such primed MSCs may secrete lineage-specific reparative factors that enhance tissue repair and regeneration.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"269-279"},"PeriodicalIF":2.6000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regenerative medicine","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1080/17460751.2026.2665223","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/28 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0
Abstract
The therapeutic efficacy of Mesenchymal stromal cells (MSCs) has been attributed to two mechanisms: one, the transdifferentiation of MSCs into tissue-specific cells and their integration into the affected tissue, and two, the reparative effects of their secretome. While the latter mechanism is now widely accepted, the ability of MSCs to transdifferentiate into non-mesodermal lineages remains highly debated. Nonetheless, several recent studies have shown that MSCs can differentiate into non-mesodermal lineages under specialized conditions. These studies are reviewed here. Notably, cultured MSCs exhibit activation of stress-kinases, and inhibition of these kinases has been shown to enhance the regenerative potential of MSCs; however, the underlying mechanisms involved in this improved potency remain poorly understood. This review also covers existing literature on the effects of stress kinase inhibition on MSC differentiation and functional potency, with an emphasis on therapeutic implications. Here, we propose a novel hypothesis that under conventional culture conditions, stress kinases negatively regulate the differentiation potency of MSCs and limit their multi-lineage potential. Inhibition of these kinases may not drive full lineage commitment that could qualify as transdifferentiation, but instead induce a quasi-differentiated or "primed" MSC state. Such primed MSCs may secrete lineage-specific reparative factors that enhance tissue repair and regeneration.
期刊介绍:
Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization.
Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community.
Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.